New anti-dysmenorrhoea drug in the pipeline by Vantia Therapeutics. It acts via the V1a blockade which leads to a reduction of the contractions and thus pain during menstrual cycle.
128 British and American women participate in phase 2 clinical trials at the moment.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου